Royalty Pharma (RPRX) Intangibles (2019 - 2021)
Royalty Pharma (RPRX) posted Intangibles of $5.7 million for Q4 2021, down 50.55% sequentially from $11.5 million in Q3 2021, and down 80.22% YoY from $28.7 million in Q4 2020.
Royalty Pharma (RPRX) Intangibles (2019 - 2021) Analysis & Trends
Royalty Pharma has reported Intangibles for 3 years, with the latest figure at $5.7 million in Q4 2021.
- Quarterly Intangibles fell 80.22% year-over-year to $5.7 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $5.7 million (down 80.22% YoY) and the FY2021 annual result came in at $5.7 million, down 80.22% from the prior year.
- Intangibles retreated to $5.7 million in Q4 2021 per RPRX's latest filing, from $11.5 million in the prior quarter.
- Over five years, Intangibles peaked at $51.7 million in Q4 2019 and troughed at $5.7 million in Q4 2021.
- A 3-year average of $26.6 million and a median of $25.8 million in 2020 frame the typical range for Intangibles.
- The sharpest annual moves came in 2020 and 2021: Intangibles sank 44.58% in 2020, then tumbled 80.22% in 2021.
- Over 3 years, Intangibles stood at $51.7 million in 2019, then tumbled by 44.58% to $28.7 million in 2020, then sank by 80.22% to $5.7 million in 2021.
- According to Business Quant data, Intangibles over the past three periods registered $5.7 million, $11.5 million, and $17.3 million for Q4 2021, Q3 2021, and Q2 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 5.67 Mn |
| Sep 30, 2021 | 11.47 Mn |
| Jun 30, 2021 | 17.26 Mn |
| Mar 31, 2021 | 23.00 Mn |
| Dec 31, 2020 | 28.67 Mn |
| Sep 30, 2020 | 34.46 Mn |
| Jun 30, 2020 | 40.26 Mn |
| Dec 31, 2019 | 51.72 Mn |